Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

Clinical lung cancer - 1 Jun 2022

Veillon Remi, Sakai Hiroshi, Le Xiuning, Felip Enriqueta, Cortot Alexis B, Smit Egbert F, Park Keunchil, Griesinger Frank, Britschgi Christian, Wu Yi-Long, Melosky Barbara, Baijal Shobhit, Jr Gilberto de Castro, Sedova Michaela, Berghoff Karin, Otto Gordon, Paik Paul K

Abstract excerpt

INTRODUCTION: The MET inhibitor tepotinib demonstrated durable clinical activity in patients with advanced MET exon 14 (METex14) skipping NSCLC. We report detailed analyses of adverse events of clinical interest (AECIs) in VISION, including edema, a class effect of MET inhibitors. PATIENTS AND METHODS: Incidence, management, and time to first onset/resolution were analyzed for all-cause AECIs, according to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Creatinine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nausea

Share to Piperidines

Share to Pleural Effusion

Share to Pyridazines

Share to Vomiting

Source

Open in PubMed Open full text

Identifiers

PMID: 35466070
DOI: 10.1016/j.cllc.2022.03.002
PMCID: PMC10068910

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.PMID 35466070Read ↗

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Semantic proximity Read ↗

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.Semantic proximity Read ↗

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations.Semantic proximity Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.Semantic proximity Read ↗

A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).Semantic proximity Read ↗

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status.Semantic proximity Read ↗

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.Semantic proximity Read ↗

Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.